🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Recruitingn/aAges 18 Years - anyAllXingshun Qi
NCT04662918 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients with liver cirrhosis; 2. Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia; 3. Adults (age≥18 years old). Exclusion Criteria: 1. Components of Child-Pugh, MELD, and CAGIB scores are not available; 2. In-hospital outcomes are not evaluable.
💊

What it tests

  • Not listed
📍

Where

23 sites
The Wright Center for Graduate Medical Education, 501 S. Washington Avenue
Scranton, United States
São Paulo State University (UNESP), Botucatu Medical School
São Paulo, Brazil
Beijing Youan Hospital, Capital Medical University
Beijing, China
The Seventh Medical Center of Chinese PLA General Hospital
Beijing, China
First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
First Affiliated Hospital of Nanchang University
Nanchang, China
The Six People's Hospital of Dalian
Dalian, China

…and 15 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy